ILICOGENIX
A Chemical Biology Company
Programmable, Personalized Medicine At Scale!
Many Molecules, Many Targets, Many Cures
TM
Our Vision
Approach N=1 For As Many Diseases As Possible
Develop drugs that are not just prescribed but DESIGNED for individual patients
We are building a programmable platform capable of addressing disease heterogeneity at the level of individual targets & patients using tunable, ultra-precise therapeutics
Our Technology
Assembled, Not Developed
A Novel Platform For Drug Design: Mixing & Matching Pre-generated Chemical-Building-Blocks To "Assemble" New Therapeutics
TM
Our work expands the concept of "chemical knockouts" to a proteome-wide scale; we can rapidly design ligands to create knockouts
We associate inhibitory small-molecule/peptide ligands with targets to create Target-Ligand Pairs (TLPs), our functional units (chemical blocks) for development
TLP Library Against Specific Protein Groups
We are generating TLPs against large groups of proteins
TLPs Against
400+
Kinases Implicated In Disease
(other target groups to follow)
The same TLPs can be mixed & matched to create responsive, customized therapies, addressing both disease & patient heterogeneity across various areas!
Proof-Of-Concept: We have demonstrated that small molecules generated using our technology are biologically active, inhibit in a concentration dependent manner and have Kd in the low micro-molar range (we are now tuning our platform to generate nano-molar range molecules). We generated a brand new antibacterial and an anti-CDK molecule in under 3 months for ~$5000
Disease Area/s
Rare Cancers As The Perfect Gateway To Personalized Medicine
Our First Disease Area: Ewing Sarcoma
Ewing Sarcoma is a devastating pediatric rare cancer with no FDA approved therapies and a bad prognosis.
Silicogenix has successfully designed small molecules against EWS-FLI1, the primary driver of Ewing Sarcoma
Pipeline
[As of May, 2026]
What's new at SGX
Full new release here
A BIG thank you to our partners
Startup Programs
-
April 2026: Silicogenix is happy to announce initial engagement with Georgetown University faculty and the tech transfer office for work on Ewing Sarcoma. Watch for more announcements!
-
February 2026: Silicogenix is very happy to onboard Dr. Babu Boga, former Head of Global External Chemistry at Zentalis Pharma as MedChem Consultant for the Ewing Sarcoma program. Welcome Dr. Boga!
-
December 2025: Silicogenix is now part of Microsoft for Startups!!
-
September, 2025: Dr. Noah Federman, Glaser Chair of Pediatric Sarcomas, joins Silicogenix as an Advisor and Key Opinion Leader (KOL) for the Ewing Sarcoma program
-
June 10, 2025: We are extremely proud to announce our partnership with Bioduro (see announcement towards the top of this webpage). Many thanks to the Bioduro team.
-
SGX establishes a Technical Advisory Panel (TAB) with Subbu Iyer, Karan Syal, Tim Sears and Vishv Jeet as members help guide deep dives into computational and engineering tool development (March 2025)
-
Tim Sears, Karan Syal and Alok Singhania to join SGX as Advisors starting March 2025!
-
SGX debuts its first CADDE-designed "lead-series" with known precursors from a CRO Jan 3, 2025! Getting ready for our first pre-clinical program in CLL!
-
SGX welcomes 3 new engineers starting November 1, 2024! Welcome aboard Juan, JD, Paulina!
-
SGX held its first strategy offsite on September 11, 2024 at VC Nest in Palo Alto! Many thanks to Lochan Alagh for making the space available.
-
SGX welcomes Ryan Flynn, Ph.D. (Harvard, Savant Ventures) to the team as Strategic Advisor
-
SGX welcomes Kevin Lynch, Ph.D. (ex CBO Recursion, Notable; ex VP Abbott, Abbvie, Vir) to the team.
Team
Shailesh Date, Ph.D.
Co-Founder & CEO
CEO, LRC Systems
Assoc. Adj. Professor, UCSF
Comp. Bio, Biophysics, Inf. Diseases
Jose Jaramillo, Ph.D.
Co-Founder & CTO
Sr. Scientist & Head of High Perf. Computing Research Ctr, LRC
Prof. of Computer Engineering, UTP
Instructor, UCSF
Former Fulbright Fellow (@Purdue)
Photonics, Quantum Computing
Dan Serna, MS
Sr. Engineer
AI
Jose Duarte
Engineer & TechOps Manager
Math, AI, Autonomous agents
Paulina Escobar
Chemist
Computational Chemistry
Juan Aguirre
Engineer
AI, Databases
Surabhi Rathore, Ph.D.
Scientist
Structural Biology
Engie Arias
Intern
Bioinformatics
Scientific Advisory Board (SAB)
Andrew Calabrese, Ph.D.
Acting CSO, Silicogenix
Member, SAB
Founding CSO, Animol Discovery;
Founder Revagenix
Ex. Pfizer, Celegene, AgriMetis
Lee Swem, Ph.D.
Member, SAB
CDO @ Kanvas Bio
Ex CSO FedBio & Achaogen,
Ex. Genentech
Subramanian Iyer, Ph.D.
Acting CAIO, Silicogenix
Member, SAB
Member, TAB
SVP of AI, QXO
Ex Head of AI @Target
Ex. Goldman Sachs, Google
Technical Advisory Board (TAB)
Tim Sears, Ph.D.
Member, TAB
Head of Software Applications, Groq
Ex. Target, Goldman Sachs, Morgan Stanley, Lehman Brothers
Karan Syal, Ph.D.
Member, TAB
Head, AI Partnerships, Reveal Health
Founder & CEO, iVIzz (exited)
Ex. Genentech
Vishv Jeet, Ph.D.
Member, TAB
Quantitative Trading Specialist
Founder, Mindtapp.app
Ex VP Research, PGIM
Ex. Assoc. Dir, MSCI Private Capital
Business Development
Kevin Lynch, Ph.D.
Strategic Advisor
Ex CBO Recursion, Notable
Ex VP Abbvie, Vir
Ryan Flynn, M.D. Ph.D.
Strategic Advisor
Asst. Professor, Harvard
Savantus Ventures (not as investor)
Alok Singhania
Partner Gridscape
Ex. CEO/Co-Founder/President Blindfish, Mobifusion, Info Objects
Josh Siedenfeld, JD
Legal Counsel
DLA Piper
Dana White, MBA
Finance Director
Engineroom
(Note: SGX appointment not through Engineroom)
Other Advisors
Nilesh Rajadhyax, MBA
COO Medquest,
Ex. CEO GEDC,
Ex. McKinsey
Vibhav Garg, MS
Pinterest; Ex Twitter,
Facebook (Meta)
Zack Abbott, Ph.D.
CEO, Zbiotics
Neil Cohen, MBA
Hexagon Federal
Don Oppenheim, MBA
COO (Retired), Meyers Nave;
Partner (Retired), Altman Weil
Get In Touch!
Mailing Address
655 Oak Grove Ave. #1417
Menlo Park, CA 94025
Office
1336 N Carolan Ave #206
Burlingame, CA 94010
Phone
(415) 570-9067
Please send an email to business-manager (at our domain)
The MAGICIANS!
_edited.png)